Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.120 -0.080 (-1.28%)
Streaming Delayed Price Updated: 11:23 AM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
41 42 Next >
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages
Via Investor Brand Network
Oregon to Become the First State to Legally Roll Out Psilocybin
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in... 
Via FinancialNewsMedia
Topics Derivatives ETFs
Psychedelic Stock Gainers And Losers From April 27, 2022
GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 3.77% at $0.28 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 26, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.61% at $0.29 
Via Benzinga
Psychedelic Drug Patenting: Still Only Scratching The Surface
Psychedelic drug R&D remains in its infancy, with dozens of psychedelics and several 
Via Talk Markets
Depression Causes Lasting Physiological Alterations to Immunity Cells
Via Investor Brand Network
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.97% at $4.97 
Via Benzinga
Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami... 
Via Benzinga
Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami... 
Via Benzinga
Three Kinds of Trauma Psychedelics Hope to Treat
Via Investor Brand Network
Cybin Presents "Why Cybin Is Investing So Heavily On Developing Novel Psychedelic Molecules" At The Psychedelic Capital Conference
Photo by Presetbase Lightroom Presets on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Field Trip Health, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 3.49% at $0.87 
Via Benzinga
Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp
Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to... 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) To Present At KCSA Psychedelics Conference
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at KCSA Psychedelics Virtual Investor Conference
Via Investor Brand Network
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
From Cybin Inc.
Via Business Wire
Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 20.83% at $0.29 
Via Benzinga
Volume of Gray Matter May Be Useful in Treatment Planning for Mental Health Conditions
Via Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment
Via Investor Brand Network
Roth Capital Reveals Top Psychedelic Picks in New Industry Report
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report... 
Via FinancialNewsMedia
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From April 20, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.69% at $0.16 LOSERS: 
Via Benzinga
EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space
Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock. In the psychedelic space, catalysts could be... 
Via Benzinga
Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.57% at $0.33 
Via Benzinga
EXCLUSIVE: How Cybin Is Developing The Next Generation Of Psychedelics
If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you. 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Pipeline Program Receives Key Patent Approval
Via Investor Brand Network
Topics Intellectual Property
Psychedelic Stock Gainers And Losers From April 18, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.66% at $0.28 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From April 14, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 2.50% at $5.32 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.